CA3004665C - Transposon system, kit comprising the same, and uses thereof - Google Patents
Transposon system, kit comprising the same, and uses thereof Download PDFInfo
- Publication number
- CA3004665C CA3004665C CA3004665A CA3004665A CA3004665C CA 3004665 C CA3004665 C CA 3004665C CA 3004665 A CA3004665 A CA 3004665A CA 3004665 A CA3004665 A CA 3004665A CA 3004665 C CA3004665 C CA 3004665C
- Authority
- CA
- Canada
- Prior art keywords
- promoter
- cell
- vector
- exogenous dna
- dna sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/90—Vectors containing a transposable element
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267270P | 2015-12-14 | 2015-12-14 | |
| US62/267,270 | 2015-12-14 | ||
| PCT/CN2016/109510 WO2017101749A1 (en) | 2015-12-14 | 2016-12-12 | Transposon system, kit comprising the same, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3004665A1 CA3004665A1 (en) | 2017-06-22 |
| CA3004665C true CA3004665C (en) | 2021-08-24 |
Family
ID=59055731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3004665A Active CA3004665C (en) | 2015-12-14 | 2016-12-12 | Transposon system, kit comprising the same, and uses thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11345926B2 (enExample) |
| JP (1) | JP6956416B2 (enExample) |
| KR (1) | KR102249982B1 (enExample) |
| CN (1) | CN108474005B (enExample) |
| AU (1) | AU2016373365B2 (enExample) |
| CA (1) | CA3004665C (enExample) |
| MX (1) | MX380289B (enExample) |
| MY (1) | MY184126A (enExample) |
| NZ (1) | NZ742068A (enExample) |
| TW (1) | TWI609960B (enExample) |
| WO (1) | WO2017101749A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US20190119636A1 (en) | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| CA3047313A1 (en) | 2016-12-16 | 2018-06-21 | B-Mogen Biotechnologies, Inc. | Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods |
| WO2019246486A2 (en) | 2018-06-21 | 2019-12-26 | B-Mogen Biotechnologies, Inc. | ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS |
| HUE068630T2 (hu) | 2018-12-10 | 2025-01-28 | Amgen Inc | Mutáns PiggyBac transzpozáz |
| EP3898993A1 (en) * | 2018-12-20 | 2021-10-27 | Poseida Therapeutics, Inc. | Nanotransposon compositions and methods of use |
| KR102990253B1 (ko) * | 2019-06-11 | 2026-07-10 | 우니베르시타트 폼페우 파브라 | 표적화된 유전자 편집 작제물 및 이의 사용 방법 |
| WO2023282730A1 (ko) * | 2021-07-09 | 2023-01-12 | 주식회사 네오젠티씨 | 트랜스포존 시스템 및 이의 용도 |
| US20260234570A1 (en) * | 2021-10-15 | 2026-08-13 | Shenzhen Eureka Biotechnology Co., Limited | Multi-transposon system |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6962810B2 (en) * | 2000-10-31 | 2005-11-08 | University Of Notre Dame Du Lac | Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac |
| MX2007014139A (es) * | 2005-05-14 | 2008-10-09 | Univ Fudan | Piggybac como una herramienta para manipulacion genetica y analisis en vertebrados. |
| US20090042297A1 (en) * | 2007-06-01 | 2009-02-12 | George Jr Alfred L | Piggybac transposon-based vectors and methods of nucleic acid integration |
| KR20080041146A (ko) * | 2007-12-13 | 2008-05-09 | 푸단 유니버시티 | 척추동물에서의 유전자 조작 및 분석을 위한 도구로서의피기백 |
| US20110311506A1 (en) | 2009-02-25 | 2011-12-22 | The Johns Hopkins University | Piggybac transposon variants and methods of use |
| DE102011118018B4 (de) | 2011-10-25 | 2017-10-26 | Plasmidfactory Gmbh & Co. Kg | Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen |
| EP3513802B1 (en) * | 2012-10-26 | 2023-11-29 | Vrije Universiteit Brussel | Vector for liver-directed gene therapy of hemophilia and methods and use thereof |
| CN102943092B (zh) * | 2012-11-20 | 2014-12-10 | 西北农林科技大学 | 一种通用型PiggyBac转座子转基因载体及其制备方法 |
| EP2922959A4 (en) * | 2012-11-20 | 2016-04-20 | Simplot Co J R | TAL-MEDIATED TRANSFER DNA INTRODUCTION |
| CN104342453A (zh) * | 2013-08-06 | 2015-02-11 | 深圳先进技术研究院 | 含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用 |
| WO2015139093A1 (en) | 2014-03-21 | 2015-09-24 | The Sydney Children's Hospitals Network (Randwick And Westmead) (Incorporating The Royal Alexandra Hospital For Children) | Stable gene transfer to proliferating cells |
| HUE052552T2 (hu) * | 2014-04-09 | 2021-05-28 | Dna Twopointo Inc | Javított nukleinsav-konstrukciók eukarióta génexpresszióhoz |
| SG10201808811QA (en) * | 2014-04-10 | 2018-11-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Method and compositions for cellular immunotherapy |
-
2016
- 2016-12-12 CA CA3004665A patent/CA3004665C/en active Active
- 2016-12-12 NZ NZ742068A patent/NZ742068A/en unknown
- 2016-12-12 JP JP2018524760A patent/JP6956416B2/ja active Active
- 2016-12-12 MY MYPI2018701786A patent/MY184126A/en unknown
- 2016-12-12 AU AU2016373365A patent/AU2016373365B2/en active Active
- 2016-12-12 TW TW105141119A patent/TWI609960B/zh active
- 2016-12-12 US US15/766,707 patent/US11345926B2/en active Active
- 2016-12-12 WO PCT/CN2016/109510 patent/WO2017101749A1/en not_active Ceased
- 2016-12-12 MX MX2018007203A patent/MX380289B/es unknown
- 2016-12-12 KR KR1020187017078A patent/KR102249982B1/ko active Active
- 2016-12-12 CN CN201680071463.4A patent/CN108474005B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI609960B (zh) | 2018-01-01 |
| AU2016373365B2 (en) | 2021-07-08 |
| KR102249982B1 (ko) | 2021-05-11 |
| JP6956416B2 (ja) | 2021-11-02 |
| US20180320196A1 (en) | 2018-11-08 |
| AU2016373365A1 (en) | 2018-05-17 |
| MX2018007203A (es) | 2018-11-12 |
| CA3004665A1 (en) | 2017-06-22 |
| US11345926B2 (en) | 2022-05-31 |
| NZ742068A (en) | 2023-07-28 |
| MX380289B (es) | 2025-03-12 |
| JP2019503653A (ja) | 2019-02-14 |
| KR20180092989A (ko) | 2018-08-20 |
| WO2017101749A1 (en) | 2017-06-22 |
| CN108474005B (zh) | 2022-10-21 |
| MY184126A (en) | 2021-03-19 |
| CN108474005A (zh) | 2018-08-31 |
| TW201720926A (zh) | 2017-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11345926B2 (en) | Transposon system, kit comprising the same, and uses thereof | |
| ES2887776T3 (es) | Vectores de ADN no integradores para la modificación genética de células | |
| EP3359676B1 (en) | Transposon system, kit comprising the same, and uses thereof | |
| AU2024202171A1 (en) | Novel OMNI-50 CRISPR nuclease | |
| AU2018264636B2 (en) | Artificially manipulated immune cell | |
| EP4143305A2 (en) | Engineered central nervous system compositions | |
| US20220378822A1 (en) | Combinatorial cancer immunotherapy | |
| US20230302134A1 (en) | Compositions and methods for engineering and selection of car t cells with desired phenotypes | |
| JP2025188209A (ja) | ゲノム編集初代ｂ細胞ならびに作製方法および使用方法 | |
| US20250332287A1 (en) | Identification of tissue-specific extragenic safe harbors for gene therapy approaches | |
| CN118632622A (zh) | 突变型肌纤蛋白疾病模型及其用途 | |
| AU2022325958A1 (en) | Novel omni 115, 124, 127, 144-149, 159, 218, 237, 248, 251-253 and 259 crispr nucleases | |
| AU2022386792A1 (en) | Systems and methods for trans-modulation of immune cells by genetic manipulation of immune regulatory genes | |
| US20230140346A1 (en) | Promoter Sequences for In Vitro and In Vivo Expression of Gene Therapy Products in CD3+ Cells | |
| WO2026107088A1 (en) | Dual car constructs and methods of use | |
| HK40115053A (en) | Novel omni crispr nuclease | |
| Alves | Escherichia coli Genome Engineering For Improved Minicircle Production | |
| HK40111655A (en) | Novel omni 115, 124, 127, 144-149, 159, 218, 237, 248, 251-253 and 259 crispr nucleases | |
| WO2026080393A1 (en) | Compositions and methods for use in car cell therapies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20201118 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20240918 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED Effective date: 20240918 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - SMALL Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241204 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241204 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241204 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250313 |
|
| R13 | Change to the name of applicant or owner recorded |
Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250723 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - SMALL Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251020 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251020 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260402 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260402 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20260514 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260514 Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260514 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260526 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260729 |